Lab testing is included in your $99 monthly subscription and processed through Quest Diagnostics 1,500+ locations nationwide
With deep expertise in peptide characterization, advanced analytical technologies, and regulatory-aligned development strategies, ResolveMass enables companies to accelerate generic Tirzepatide programs with confidence
SURMOUNT-1 data show that 48% of patients on 15mg maintenance experienced nausea, 29% experienced diarrhea, 24% experienced vomiting, and 19% experienced constipation during the first four weeks at peak dose
Patients and healthcare professionals need not only access to effective treatments, but also trustworthy information, realistic expectations and a clear understanding of the entire treatment journey
Summary: GLP-1 receptor agonists are not specifically licensed for menopausal weight gain but may be prescribed for women meeting obesity treatment criteria (BMI 35 kg/m with comorbidities) during the menopausal transition